Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2006

View Archived Issues

Medarex looks back on achievements

Cangrelor demonstrates advantages over abciximab in patients undergoing PCI

Mepolizumab decreases eosinophilia in hypereosinophilic syndromes, esophagitis

Novel anti-HGF MAb L2G7 exhibits profound effects in mice bearing intracranial glioma xenografts

Targeted Genetics supports plans for 2006 through new financing

Dusa closes acquisition of Sirius Laboratories

Pharmos to acquire Vela Pharmaceuticals

Enrollment completed in SPIRIT III study of Xience V stent

Roche expands manufacturing network for production of Tamiflu

GenVec expands TNFerade phase II study into phase II/III trial

Edison and university partners establish mitochondrial disease collaboration

AdvaTab Cetirizine completes pharmacokinetic study

Phase II pilot study assesses Oxycyte in traumatic brain injury

Novavax collaborative HIV program receives additional funding

LymphoSign completes preclinical testing of LS-104

V-1003 superior to Vicodin for pain relief

Significant decline in HBV viral load in pradefovir study

Sativex produces improvement in MS-related spasticity

Human Genome Sciences reports new phase II data for Albuferon

ALK5 inhibitor a novel therapeutic approach for the treatment of fibrosis

Recent patents impart new therapeutic agents for cancer

New agents for treating thrombocythemia reported in recent Shire patent

Targeting the M. tuberculosis proteasome for novel tuberculosis therapies

ARRY-649: A novel, highly potent KSP inhibitor from Array BioPharma

The glycolytic enzyme GAPDH as a target for neuroprotection

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...